HC Wainwright Has Negative Forecast for PLX FY2026 Earnings

Protalix BioTherapeutics, Inc. (NYSE:PLX) – Equities research analysts at HC Wainwright reduced their FY2026 earnings per share estimates for Protalix BioTherapeutics in a report issued on Wednesday, November 11th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn $0.28 per share for the year, down from their prior estimate of $0.29. HC Wainwright has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.01 per share. HC Wainwright also issued estimates for Protalix BioTherapeutics’ Q4 2027 earnings at $0.02 EPS.

Protalix BioTherapeutics Trading Up 9.4%

NYSE:PLX opened at $3.13 on Thursday. The firm has a market capitalization of $252.19 million, a price-to-earnings ratio of -24.08 and a beta of 0.01. The business’s 50-day moving average price is $2.67 and its two-hundred day moving average price is $2.44. Protalix BioTherapeutics has a 1-year low of $1.65 and a 1-year high of $3.19.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PLX. Voya Investment Management LLC increased its stake in Protalix BioTherapeutics by 55.2% during the 3rd quarter. Voya Investment Management LLC now owns 16,634 shares of the company’s stock worth $46,000 after purchasing an additional 5,917 shares in the last quarter. Russell Investments Group Ltd. grew its holdings in shares of Protalix BioTherapeutics by 903.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 248,557 shares of the company’s stock valued at $686,000 after acquiring an additional 223,792 shares in the last quarter. Ashton Thomas Private Wealth LLC acquired a new position in shares of Protalix BioTherapeutics during the 3rd quarter worth approximately $44,000. WINTON GROUP Ltd acquired a new stake in Protalix BioTherapeutics in the second quarter valued at $130,000. Finally, Two Sigma Securities LLC bought a new position in Protalix BioTherapeutics during the second quarter worth about $41,000. 16.53% of the stock is owned by institutional investors and hedge funds.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc. is a biopharmaceutical company that develops and commercializes recombinant therapeutic proteins for the treatment of rare and serious diseases. The company is headquartered in Israel and uses its proprietary ProCellEx plant-cell-based protein expression platform to produce biologic medicines. Protalix’s commercial products include Elfabrio (pegunigalsidase alfa), a treatment for adults with Fabry disease, and Elelyso (taliglucerase alfa), an enzyme replacement therapy for adults with Gaucher disease.